Hello,
Today in
Color got its start during the consumer DNA testing boom. Now, the CEO of the $1.5 billion startup tells us why he thinks genetics are just one aspect of how the upstart will overhaul healthcare.
- Insider sat down with Othman Laraki, CEO of
Color , the onetime consumer genetics startup that achieved $1.5 billion "unicorn" status in January. - Laraki said the pandemic helped Color, which started during the direct-to-consumer DNA test boom, realize its most valuable product: digital health infrastructure.
- Through Color's genetic testing efforts, Laraki realized Color could provide a pathway to basic care access, a significant deviation compared to others in the space like 23andMe.
Read the full story from Patricia Kelly Yeo here>>
Open enrollment just started and changes to Obamacare in Biden's stimulus could mean cheap or free health insurance for millions of people
- Millions of middle-income people have been shut out of
Obamacare since they earn more than $51,000. - The $1.9 trillion stimulus package in Congress would make
health insurance premiums cheaper. - It would also pick up most of the tab for COBRA plans to help laid-off workers.
Read the full story from Kimberly Leonard here>>
Experts warned of the digital divide for years. Now it's 'life or death' as people struggle to sign up for online COVID-19 vaccinations.
- Underserved populations in the US struggle to get COVID-19 vaccines as providers rely on the web.
- About 38 million Americans don't have internet literacy, and 25 million don't have internet access.
- The barrier is another way underserved populations are bearing the brunt of the pandemic.
Read the full story from Natasha Dailey here>>
More stories we're reading:
- The world has lost 20.5 million years of life because of premature COVID-19 deaths, a new study found (Insider)
- Here's why we can't make vaccine doses any faster (ProPublica)
- Seniors are recruiting college kids to help them get vaccine appointments (The Wall Street Journal)
- The first dose of the Pfizer vaccine is 85% effective, Israeli study finds (Insider)
- Lydia